JLE

Hépato-Gastro & Oncologie Digestive

MENU

Cholangite biliaire primitive : une autre actualité que le changement de nom ? Volume 25, numéro 9, Novembre 2018

  • [1] Angulo P., Lindor K.D., Therneau T.M. Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid. Liver. 1999;19:115-121.
  • [2] Pares A., Caballeria L., Rodes J. Excellent long-term survival in patients with primary biliary cirrhosisand biochemical response to ursodeoxycholic acid. Gastroenterology. 2006;130:715-720.
  • [3] Corpechot C., Abenavoli L., Rabahi N. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology. 2008;48:871-877.
  • [4] Kuiper E.M., Hansen B.E., de Vries R.A. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. Gastroenterology. 2009;136:1281-1287.
  • [5] Kumagi T., Guindi M., Fischer S.E. Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis. Am J Gastroenterol. 2010;105:2186-2194.
  • [6] Corpechot C., Chazouillères O., Poupon R. Early primary biliary cirrhosis: Biochemical response to treatment and prediction of long-term outcome. J Hepatol. 2011;55:1361-1367.
  • [7] Carbone M., Sharp S.J., Flack S. The UKPBC risk scores: Derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cirrhosis. Hepatology. 2016;63:930-950.
  • [8] Lammers W.J., Hirschfield G.M., Corpechot C. Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy. Gastroenterology. 2015;149:1804-1812.
  • [9] The diagnosis and management of patients with primary biliary cholangitis. J Hepatol. 2017;67:145-172. EASL Clinical Practice Guidelines